Using the Braak staging for neurofibrillary changes as an objective indicator of the progression of Alzheimer's disease, we have performed a systematic search for global gene expression changes in the prefrontal cortex during the course of Alzheimer's disease. In the prefrontal cortex, senile plaques and neurofibrillary changes start to appear around Braak stage III, allowing for the detection of changes in gene expression before, during and after the onset of Alzheimer's disease neuropathology. Two distinct patterns of tightly co-regulated groups of genes were observed: (i) an increase in expression in early Braak stages, followed by a decline in expression in later stages (the UPDOWN clusters; containing 865 genes) and (ii) a decrease in expression in early Braak stages, followed by an increase in expression in later stages (the DOWNUP clusters; containing 983 genes). The most profound changes in gene expression were detected between Braak stages II and III, just before or at the onset of plaque pathology and neurofibrillary changes in the prefrontal cortex. We also observed an increase in intracellular beta amyloid staining from Braak stages I to III and a clear decrease in Braak stages IV to VI. These data suggest a link between specific gene expression clusters and Alzheimer's disease-associated neuropathology in the prefrontal cortex. Gene ontology over-representation and functional gene network analyses indicate an increase in synaptic activity and changes in plasticity during the very early pre-symptomatic stage of the disease. In later Braak stages, the decreased expression of these genes suggests a reduction in synaptic activity that coincides with the appearance of plaque pathology and neurofibrillary changes and the clinical diagnosis of mild cognitive impairment. The interaction of the ApoE genotype with the expression levels of the genes in the UPDOWN and DOWNUP clusters demonstrates that the accelerating role of ApoE-e4 in the progression of Alzheimer's disease is reflected in the temporal changes in gene expression presented here. Since the UPDOWN cluster contains several genes involved in amyloid precursor protein processing and beta amyloid clearance that increase in expression in parallel with increased intracellular beta amyloid load, just before the onset of plaque pathology in the prefrontal cortex, we hypothesize that the temporally orchestrated increase in genes involved in synaptic activity represents a coping mechanism against increased soluble beta amyloid levels. As these gene expression changes occur before the appearance of Alzheimer's disease-associated neuropathology, they provide an excellent starting point for the identification of new targets for the development of therapeutic strategies aimed at the prevention of Alzheimer's disease. Keywords: microarray; Alzheimer's disease; Braak stage; beta amyloid; prefrontal cortex Abbreviations: Ab = beta amyloid; APP = amyloid precursor protein; EGR1 = early growth response 1; PACAP = adenylate cyclase activating polypeptide 1 (pituitary); PCR = polymerase chain reaction; PCSK1 = proprotein convertase subtilisin/kexin type 1; PSEN2 = presenilin 2; RER1 = retention in endoplasmic reticulum 1; SST = somatostatin; ZNT3 = zinc transporter 3
Introduction
Alzheimer's disease is the most common form of dementia, and its prevalence increases exponentially with age. Neuropathologically, Alzheimer's disease is characterized by the presence of extracellular deposits of beta amyloid protein (Ab) in diffuse and neuritic plaques, and neurofibrillary changes comprised of intracellular deposits of hyperphosphorylated tau protein in neurofibrillary tangles, dystrophic neurites and neuropil threads (Braak et al., 1998 ). Alzheimer's disease progression can be monitored by the presence of tangle-bearing neurons in well-defined brain areas, and is classified into six Braak stages (I-VI) (Braak and Braak, 1991; Braak et al., 2006) . In addition, a Braak stage of 0 means that no neurofibrillary changes are detected in any part of the brain. Braak stages I and II are characterized by the presence of only a few neurofibrillary changes in the transentorhinal region of the brain. These stages are not associated with any sign of cognitive decline. Braak stages III and IV, generally manifested clinically as mild cognitive impairment, are defined by increased neurofibrillary changes pathology in the transentorhinal cortical area, the hippocampus and limbic areas. In these stages, the first neurofibrillary changes in the prefrontal cortex can also be observed. Finally, in Braak stages V and VI, when neurofibrillary changes-associated neuropathology spreads throughout most parts of the neocortex, the clinical diagnosis of dementia is made. In the last two decades, mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) have been found to cause autosomal dominant, early onset familial Alzheimer's disease (Bertram and Tanzi, 2005) . Interestingly, these genes are all involved in altering the levels of Ab, the main component of extracellular plaques in Alzheimer's disease. However, gene mutations only account for a small subset of Alzheimer's disease cases; the vast majority (495%) of Alzheimer's disease cases are of sporadic origin. The main risk factor for sporadic Alzheimer's disease is age (Yankner et al., 2008) . Variations in the apolipoprotein E (ApoE) gene significantly alter the susceptibility for Alzheimer's disease, but are not causal to Alzheimer's disease (Mayeux, 2006) . Furthermore, two recent genome-wide association studies identified a link between variations in the clusterin (CLU), phosphatidylinositol binding clathrin assembly protein (PICALM) and complement component (3b/4b) receptor 1 (CR1) genes and late onset Alzheimer's disease (Harold et al., 2009; Lambert et al., 2009) . However, despite extensive research efforts in the last few decades, the neurobiological processes that cause sporadic Alzheimer's disease remain poorly understood.
A limited number of whole-genome microarray experiments have recently been conducted on human post-mortem Alzheimer's disease brain material (reviewed in Reddy and McWeeney, 2006) . Most of these studies focus on the comparison between controls and end-stage Alzheimer's disease, apart from a few notable exceptions (Blalock et al., 2004; Katsel et al., 2007) . However, to our knowledge, no reports investigated patterns of gene expression throughout the entire course of Alzheimer's disease. This is of importance, as such a study would allow for the detection of groups of genes with similar expression profiles across the Braak stages. Furthermore, the ability to discriminate between early and late changes might provide insight into which transcriptional mechanisms are potentially causative, or merely secondary to the disease process.
To investigate changes in gene expression during the progression of Alzheimer's disease, we have generated genome-wide gene expression profiles from the medial frontal gyrus of 49 clinically well-characterized subjects, stratified according to Braak stage for neurofibrillary changes pathology. We selected the prefrontal cortex because it is affected relatively late in the Alzheimer's disease process (Braak and Braak, 1991) . This allowed us to investigate potential gene expression alterations before, during and after the onset of Alzheimer's disease-associated neuropathological changes.
Materials and methods

Subjects
Snap-frozen human medial frontal gyrus brain samples were obtained from the Netherlands Brain Bank, Amsterdam. Written informed consent for a brain autopsy and the use of the material and clinical information for research purposes was obtained by the Netherlands Brain Bank from the donor or the next of kin. All individuals were neuropathologically systematically investigated as described earlier (van de Nes et al., 1998) . For each individual, neuropathological reports, including Braak staging for neurofibrillary changes and neuritic plaques (Braak and Braak, 1991) and clinical reports were available. For each of the six Braak stages for neurofibrillary changes, seven individuals were included. Furthermore, seven individuals without any neurofibrillary changes pathology were included as Braak stage 0. No neuropathology other than that characteristic for Alzheimer's disease or associated with normal ageing was observed in the prefrontal cortex of any of the individuals. No subjects were included from families with a history of familial Alzheimer's disease. Included patients showed no signs of neuropathological or psychiatric disease and were not treated with corticosteroids unless mentioned otherwise (Supplementary Table 1 ). For each Braak stage, the median value of plaque levels (no, few, substantial or many plaques) in the prefrontal cortex was determined, and the number of patients with neurofibrillary changes pathology in each Braak stage was assessed (Fig. 1 ).
Samples were matched as closely as possible for sex, age, post-mortem interval, CSF, pH and ApoE genotype (Table 1) . It is now evident that agonal state is a major confounder in gene expression studies (Tomita et al., 2004) . CSF pH is a marker for agonal state, therefore only samples with high CSF pH values were included (mean pH 6.6, range 6.2-7.4). Furthermore, as microarray experiments are sensitive to RNA degradation, only samples with a relatively high RNA integrity number (mean 8.3, range 6.5-9.6) were used (also see section on RNA isolation). Due to the stringent pH and RNA integrity number selection criteria, the final set of samples contained small but significant differences between Braak stages for age, post-mortem interval and RNA integrity number (Kruskal-Wallis test, P-value 50.05). The minor differences in RNA integrity have, however, not influenced our conclusions, as we were able to confirm transcript levels in our dataset by quantitative polymerase chain reaction (qPCR) analysis, which is insensitive to the amount of RNA degradation observed in our dataset (Fleige and Pfaffl, 2006) . Furthermore, when we correlated gene expression levels with age or post-mortem interval, we did not observe any significant correlations (data not shown). We observed no overlap between these genes and the genes selected by the Braak stage ANOVA (for description of ANOVA-based gene selection see below).
Tissue dissection and RNA isolation
Tissue dissection was performed using a cryostat. For each sample, between 20 and 30 sections of 50 mm were cut. Grey matter areas were dissected out inside the cryostat using pre-chilled scalpels, collected in pre-chilled 2 ml tubes and immediately put on dry ice. Total RNA was isolated using a combination of Trizol-based and RNeasy Mini Kit RNA isolation methods. Briefly, samples were homogenized in ice-cold Trizol (Life Technologies, Grand Island, NY, USA, 3 ml Trizol per 100 mg tissue). After phase separation by addition of chloroform, the aqueous phase was mixed with an equal volume of 70% RNase-free ethanol. Samples were then applied to an RNeasy Mini column (Qiagen, Valencia, CA, USA) and processed according to manufacturer's instructions. RNA yields and purity were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNA integrity was determined by the RNA integrity number, as measured by the Agilent 2100 bioanalyser (Agilent Technologies, Palo Alto, CA, USA). Overall, the isolated RNA was of high integrity (average RNA integrity number 8.3, range 6.5-9.6; Table 1 ).
Sample labelling and microarray hybridization
For microarray analysis, Agilent 44K Whole Human Genome arrays (Agilent Technologies, Part Number G4112A) were used. Sample labelling and microarray hybridization were performed according to manufacturer's instructions. Briefly, for each sample, two aliquots of 500 ng of RNA were linearly amplified and fluorescently labelled with either Cy3-CTP or Cy5-CTP (Perkin Elmer) using the Agilent Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). Prior to hybridization, equal amounts (1 mg) of Cy3-and Cy5-labelled RNA were hydrolyzed for 30 min at 60 C in 1Â fragmentation buffer (Agilent Technologies). The fragmented targets were hybridized to a microarray by incubating for 17 h at 60 C in 1Â target solution (Agilent Technologies) in a rotating hybridization chamber. Specifically, each hybridization consisted of two individual samples, one labelled with Cy3 and one with Cy5. None of the samples were pooled. For example, on the first array sample BR2.2 (Cy3) was hybridized against BR1.5 (Cy5). A full description of all hybridizations can be found in Supplementary Table 2 and a schematic overview of the hybridization design in Supplementary Fig. 1 . After hybridization, the arrays were washed at room temperature for 5 min in 6Â salinesodium phosphate-EDTA (SSPE)/0.005% N-Lauroylsarcosine (Sigma-Aldrich, St Louis, MO, USA), 1 min in 0.06Â SSPE/0.005% N-Lauroylsarcosine and 30 s in acetonitrile (Sigma-Aldrich), then dried in a nitrogen flow. Microarrays were scanned using an Agilent DNA Microarray Scanner at 5 mm resolution and 100% Figure 1 Neurofibrillary tangle and senile plaque pathology in the prefrontal cortex Representation of Alzheimer's disease-associated neuropathological alterations in the prefrontal cortex of patients included in this study. The solid line represents the number of patients with tangles (left y-axis). The dotted line represents the median senile plaque pathology (right y-axis). A detailed description of neuropathology for each subject can be found in Supplementary 
Microarray normalization and single gene analysis
Raw expression data were imported into the R statistical processing environment using the LIMMA package in Bioconductor (http://www .bioconductor.org). All features for which one or more foreground measurements were flagged as saturated or as a non-uniformity outlier by the feature extraction software were excluded from further analysis. A total of 39 510 features passed these constraints. As overall background levels were very low, no background correction was performed.
We have recently demonstrated that the analysis of the separate intensity channels (the individual Cy3 and Cy5 signals) yields more reproducible results than the standard ratio-based approach (the ratio between the Cy3 and Cy5 channels) for dual-colour microarray datasets (Bossers et al., 2010) . We have therefore opted for an intensity-based analysis of this dataset. Consequently, the intensity distributions within and between arrays were normalized using the 'quantile' algorithm in LIMMA. The log2-transformed intensity measurements per sample were used in all following analyses. To check for hybridization artefacts, the individual intensities were clustered using hierarchical clustering. As each sample was hybridized twice, possible outliers could be identified by an aberrant distance between the duplicate measurements. Four such cases were detected. For these cases, the corresponding hybridization was repeated and the outlier removed from further analysis ( Supplementary Fig. 2 ). The mean expression for each feature per sample was calculated by averaging the two measured intensities to yield the final normalized dataset.
To detect genes with a significant interaction with Braak stage, a one-way analysis of variance (ANOVA) approach using Braak stage as grouping factor was used. Raw P-values were corrected for multiple testing using the Benjamini-Hochberg algorithm. Corrected P-values 50.05 were considered significant.
Cluster analysis of Braak stage profile data
In order to follow the expression of individual transcripts during the course of Alzheimer's disease, expression profiles over the consecutive Braak stages were constructed. First, for each transcript, a 2log ratio was calculated by subtracting the mean expression level of all subjects from the average expression value per Braak stage. Next, the ratio value per Braak stage was calculated by averaging the seven individual corresponding ratios. This yielded Braak stage profiles for each transcript.
To enable Gene Ontology over-representation analysis (which is a gene-level annotation) on sets of transcripts with similar profiles, all profiles of transcripts belonging to the same gene were averaged. This resulted in a set of Braak stage profiles of 29 813 genes and expressed sequence tags over the Braak stages. Similar Braak stage profiles were grouped together by means of clustering (fuzzy clustering using the MFuzz package, version 1.6.0 in Bioconductor). The Braak stage dataset was clustered into 24 separate clusters to allow for the detection of the possible occurrence of small but significant differences between clusters.
Gene ontology over-representation analysis
The features on the array were annotated with Gene Ontology identifiers using the hgug4112a library (version 2.0.1) in Bioconductor. Out of the 29 813 features encoding unique genes and expressed sequence tags, 16 693 features were annotated with one or more Gene Ontology classes. A total of 6065 unique Gene Ontology classes were represented on the array. For the 24 gene clusters, we calculated whether there were any Gene Ontology classes significantly enriched in these clusters using the TopGO package (version 1.4.0) (Alexa et al., 2006) . Gene Ontology classes with a 'weight'-corrected P-value of 50.05 were considered significant. Only Gene Ontology classes containing !5 genes, for which at least one gene was represented in the cluster under investigation, were included in the final results table.
Pathway analysis
The Ingenuity Pathway Analysis program (Ingenuity Systems, Mountain View, CA, USA, version 7.6) was used to identify direct and indirect physical and/or functional interaction between genes in selected Braak stage profile clusters. A core analysis was performed on all genes that were members of the four most significantly changed Braak stage profile clusters, using all genes present on the array as a background dataset. This approach yielded networks of interacting genes and significantly over-represented canonical pathways.
Reverse transcription and quantitative polymerase chain reaction
Each sample was reverse transcribed using 1 mg of total RNA, random hexamer primers and SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). For each quantitative PCR reaction, 1/250 of the total complementary DNA yield was used. Transcript quantifications were carried out on an ABI 7300 sequence detection system (Applied Biosystems, Foster City, CA, USA). Each reaction was performed with the appropriate amount of complementary DNA, 3 pmol of forward and reverse primers and 10 ml 2Â SYBR green ready reaction mix (Applied Biosystems) in a total volume of 20 ml. Forward and reverse primer sequences can be found in Supplementary Table 3. Dissociation curves were generated for all wells. No primer dimers were observed.
For between-sample normalization, genes were selected that were not regulated between Braak stages, using expression stability measurements and geometric averaging of multiple internal reference genes (Vandesompele et al., 2002) . Briefly, an initial selection of 10 genes was made based on the gene expression data and reference gene data from literature. The seven most stable genes between Braak stages were selected (DHX16, ERBP, KLHDC5, TM9SF4, SNW1, AURKAIP1 and ISOC2) and for each sample a normalization factor was determined by geometric averaging of the expression values of the reference genes.
Western blots
For western blotting experiments we selected subjects from Braak stages 0, II, III, V and VI (each n = 4) from the patient collection used in the microarray experiment. Two matched Braak VI samples were used that were not included in the microarray experiment (see Supplementary Table 1) . Tissue dissection was performed as described for the microarray samples. Samples were homogenized in suspension buffer (0.1 M NaCl, 0.01 M Tris-HCl, 0.001 M ethylenediaminetetraacetic acid) containing protease inhibitors (20 mM antipain, 1 mM pepstatin, 20 mM chymostatin, 10 mg/ml leupeptin and 100 mg/ml phenylmethanesulphonylfluoride) using an ultra turrax tissue homogenizer. Homogenates were centrifuged at 14 000 rpm for 5 min at 4 C, the supernatant was collected and protein concentrations were measured using a bicinchoninic acid protein assay kit (Pierce, Thermo Scientific, Rockford, IL, USA). An aliquot of 24 mg of the samples was heated in 5Â loading buffer containing 10% sodium dodecyl sulphate and 10% b-mercaptoethanol at 65 C for 10 min. Tris-glycine sodium dodecyl sulphate polyacrylamide gel electrophoresis was performed using the BioRad Mini-PROTEAN 3 gel electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA) and proteins were wet-transferred to nitrocellulose membranes and blocked with 5% fat-free milk powder in 1Â phosphate buffered saline/0.05% Tween-20 for 1 h at room temperature. 
Immunohistochemistry
Formalin-fixed paraffin embedded blocks from medial frontal gyrus tissue samples were acquired from the Netherlands Brain Bank. About 6 mm sections were cut for 41 patients (Braak stages 0, I, II and V n = 5; Braak stage IV n = 6; Braak stages III and VI n = 7) on a Leitz microtome and mounted on SuperFrost Plus slides (Menzel-Glaeser, Braunschweig, Germany). Except for one Braak stage VI patient, all patients were taken from the microarray patient collection (Supplementary Table 1 ). Sections were deparaffinized in xylene and rehydrated in a graded ethanol series. Antigen retrieval was performed in 0.01 M citrate buffer (pH 6)/0.05% Tween-20 for 2 Â 5 min at 700 W in a microwave oven. After cooling to room temperature, sections were subjected to 10 min 70% formic acid treatment. Prior to antibody incubation, sections were incubated in a 0.5% Sudan black solution in 70% ethanol for 30 min to block lipofuscin autofluorescence. Sections were incubated with 4G8 (Signet, Dedham, MA, USA; 1:1000, directed against Aß17-24) in supermix overnight at room temperature. Cy3-conjugated donkey anti mouse IgG (Jackson Immuno Research, Newmarket, Suffolk, UK; 1:400) in supermix was used as secondary antibody for 2 h at room temperature. Cell nuclei were stained with Hoechst (Invitrogen, Molecular Probes, Eugene, OR, USA; 1:20 000). Sections were mounted with Moviol embedding medium.
The specificity of 4G8 was verified by pre-adsorption with a beta42 synthetic peptide (AnaSpec Inc, San Jose, CA, USA) spotted on gelatin-coated nitrocellulose membrane strips as described earlier (Van der Sluis et al., 1987) . In short, the peptide was spotted on the membrane (30 mg/10 cm 2 membrane strip) and fixed to the membrane with 4% paraformaldehyde in a press block overnight at room temperature. For the pre-absorption of the antibody, five strips of peptide containing membrane were consecutively incubated in 1 ml 4G8 antibody solution (Supermix, 1:1000) alternately for 3-4 h at room temperature and overnight at 4 C. In parallel, five control membrane strips without spotted peptide were incubated in 1 ml of 4G8 antibody solution. Medial frontal gyrus sections were incubated with pre-absorbed 4G8 serum or control 4G8 serum as described above. Intra-and extracellular Aß staining intensity was semi-quantitatively rated blinded to diagnosis, based on 4G8 staining intensity in all cortex layers: (i) +++ indicated strong intracellular staining or heavy plaque load; (ii) ++ indicated weaker, but obvious intracellular staining or moderate plaque load; (iii) + indicated faint intracellular staining or sporadic plaques and (iv) À indicated no intracellular staining or plaques. Photographs were taken with a Nuance FX camera (CRI, Woburn, MA, USA) for multispectral imaging on a fluorescent microscope (Zeiss Axiovert 200M, Jena, Germany) with a 40Â Plan Neofluar objective. Autofluorescence that remained after the Sudan black treatment was removed from the photographs using the Nuance 2.10.0 spectral analysis software (CRI). Image-Pro 6.3 (Media Cybernetics, Bethesda, MD, USA) was used for further image processing.
Results
To gain insight into gene expression changes during the progression of Alzheimer's disease, we performed microarray experiments on the prefrontal cortex of 49 individuals with neuropathologically well-defined Alzheimer's disease-associated neurofibrillary changes, classified according to the Braak staging for neurofibrillary changes. In total, 1071 features (2.7% of all features) representing 922 genes were found to have an interaction between expression level and Braak stage (ANOVA, Benjamini-Hochberg corrected P-value 50.05, Supplementary Table 4). All features with P50.01 are given in Table 2 . To validate the expression patterns as observed on the microarray, quantitative PCR measurements were performed on a set of 13 genes with relatively large fold changes. Indeed, the patterns of gene expression across the Braak stages were highly correlated between the microarray and quantitative PCR measurements (average r 2 = 0.57).
Furthermore, for 12 out of 13 genes, an ANOVA analysis on the quantitative PCR data confirmed the significant differences between Braak stages that were observed on the microarray (Table 3) . Several transcriptional alterations observed in our dataset are in line with earlier findings in end-stage Alzheimer's disease and thus corroborate the reliability of our microarray dataset. For example, we observed a strong decrease in somatostatin (SST) levels in more advanced Braak stages, which was found to be reduced in Alzheimer's disease neocortex and in CSF 25 years ago (Davies et al., 1980; Wood et al., 1982) . Corticotropin releasing hormone levels (May et al., 1987) and kallikrein-related peptidase 7 levels (Diamandis et al., 2004) are severely decreased in Alzheimer's disease CSF, observations that we corroborated in the Alzheimer's disease prefrontal cortex. Two members of the small heat shock protein family, heat shock 70 kDa protein 2 (HSPA2) and heat shock 27-kDa protein 2 (HSPB2), and the class I Braak stage data = log 2-transformed fold change against average of all measurements. P-value = Benjamini-Hochberg-corrected ANOVA P-value. Fold change = maximum fold change between Braak stages. Cluster = cluster assignment (see Fig. 3 and Supplementary Fig. 3 ). Only genes with P50.01 are given. The full list of significantly altered genes can be found in Supplementary Table 1. metallothioneins MT1B and MT1G are induced in end-stage Alzheimer's disease in our dataset, and have been reported to be associated with Ab pathology in Alzheimer's disease (Lukiw, 2004; Hidalgo et al., 2006; Wilhelmus et al., 2006) .
Detection of concerted gene expression changes over Braak stages
A hierarchical clustering on the average levels per Braak stage (Braak stage profiles) for the significantly regulated transcripts was performed (Fig. 2) . Interestingly, we observed a clear separation between the early stages of neurofibrillary changes pathology (Braak stages 0-III, before or at the onset of neurofibrillary changes pathology in the prefrontal cortex) and later stages (Braak stages IV-VI, after appearance of neurofibrillary changes in the prefrontal cortex), based on the expression of genes with a significant interaction between expression level and Braak stage. This finding suggests a relationship between the observed transcriptional alterations and Alzheimer's disease-associated neurofibrillary changes neuropathology. In addition, the potential presence of groups of transcripts with similar expression patterns over the Braak stages indicates co-regulation and/or functional interaction between these transcripts, and possibly provides insight into the sequence of events ultimately leading to Alzheimer's disease-associated neuropathology and degeneration. Clusters of transcripts displaying alterations in early Braak stages are expected to contain changes that are causative to mild cognitive impairment and Alzheimer's disease, whereas alterations in later Braak stages are more likely to represent secondary changes in gene expression. In the dataset of 39 510 microarray features, several features encoded the same gene. The Braak stage profiles of these features were merged, resulting in a final dataset of 29 813 gene expression profiles across the Braak stages. Using a cluster analysis, the 29 813 Braak stage profiles were divided into 24 groups of transcripts with strongly coupled expression levels ( Supplementary Fig. 3 ). We detected several clusters with pronounced and distinct alterations over the Braak stages. As the shapes of some profiles shared similarities with other profiles, a second cluster analysis was performed on the average shapes of the clusters to assess the relationship between the Braak stage clusters (Fig. 3A) . Also, for each cluster we calculated the fraction of genes differentially expressed according to the ANOVA analysis. This provided us with an indication of the significance of the observed alterations over the Braak stages (Fig. 3B) .
Several clusters stood out due to the temporal pattern of regulation over the consecutive Braak stages and the high percentage of significantly altered transcripts within these clusters (Fig. 3C) . Two distinct patterns could be observed: (i) an increase in expression in early Braak stages, followed by a decline in expression in later stages (Clusters 6 and 23 in Fig. 3C and Supplementary  Fig. 3 ; the UPDOWN clusters) and (ii) a decrease in expression in early Braak stages, followed by an increase in expression in later stages (Clusters 12 and 24 in Fig. 3C and Supplementary Fig. 3 ; the DOWNUP clusters). Interestingly, the most profound changes in gene expression were detected between Braak stages II and III, just before or at the onset of neurofibrillary changes pathology in the prefrontal cortex, suggesting a link between specific Braak profile clusters and Alzheimer's disease-associated neurofibrillary changes in the prefrontal cortex.
Functional annotation of Braak stage profile clusters
To gain insight into the biological processes associated with the different clusters of Braak stage profiles, we performed a Gene Ontology over-representation analysis to determine which Gene Ontology identifiers were significantly enriched within that cluster. The resulting lists of significantly overrepresented Gene Ontology identifiers are presented in Supplementary Table 5 . A selection of the most significant Gene Ontology identifiers (P50.01) associated with the UPDOWN and DOWNUP clusters are given in Tables 4 and 5 , respectively. Cluster 6, an UPDOWN cluster, is strongly associated with gene groups involved in synaptic activity (e.g. Gene Ontology classes 'Synaptic transmission' and 'Synapse') and nervous system development and plasticity (e.g. Gene
Ontology classes 'Nervous system development' and 'Growth cone'). Interestingly, Cluster 23, the other UPDOWN cluster, contains genes associated with quite different processes, such as ATP synthesis (e.g. Gene Ontology classes 'ATP synthesis coupled proton transport', 'Electron transport' and 'Mitochondrion') and ribosome assembly and ribosomal RNA and transfer RNA transcription and processing (e.g. Gene Ontology classes 'tRNA metabolic process', 'Ribosome biogenesis and assembly, and ribonuclease P complex'). The DOWNUP Cluster 12 contains several gene groups involved in differentiation and proliferation (e.g. Gene Ontology classes 'Protein Kinase C activation', 'Positive regulation of JNK cascade', 'Brain development' and 'Notch signalling pathway') and metal ion binding (Gene Ontology classes 'Response to metal ion', 'Cadmium ion binding' and 'Copper ion binding'). Cluster 24 is strongly associated with antigen processing gene groups (e.g. Gene Ontology classes 'Antigen processing and presentation of peptide or polysaccharide antigen via MHC Class II', 'MHC Class II protein complex' and 'MHC Class II receptor activity') and regulation of transcription (e.g. Gene Ontology classes 'DNA-dependent regulation of transcription', 'Negative regulation of transcription factor activity' and 'DNA binding').
Pathway analysis of UPDOWN and DOWNUP clusters
In addition to the Gene Ontology over-representation studies, we performed an ingenuity pathway analysis on the UPDOWN and DOWNUP clusters to obtain a more detailed understanding of the exact set of genes and gene-gene interactions that are associated with the Braak stage profiles. The canonical pathways that were significantly enriched in the DOWNUP and UPDOWN clusters were in general agreement with the Gene Ontology analysis. Examples of enriched canonical pathways include 'Oxidative phosphorylation', '14-3-3-mediated signalling', 'Mitochondrial dysfunction', 'Antigen presentation pathway' and 'GABA receptor signalling'. The full list of overrepresented pathways is given in Supplementary Table 6 . The ingenuity pathway analysis also generated a network of gene-gene interactions (Fig. 4) 
Western blot analysis and immunohistochemistry to detect changes in beta amyloid load and proteins involved in beta amyloid processing
We observed a number of genes involved in APP and Ab processing [PSEN2, RER1, ZNT3, proprotein convertase subtilisin/kexin type 1 (PCSK1), SST, adenylate cyclase activating polypeptide 1 (pituitary) (PACAP) and early growth response 1 (EGR1)] that were significantly regulated across the Braak stages, and were all part of the UPDOWN clusters. To gain more insight into the biological relevance of these changes, we studied the protein expression of PSEN2, RER1 and ZNT3 in Braak stages 0, II, II, V and VI (the Braak stage where the expression differences at the transcript level were most pronounced) using western blot analysis. Due to limited tissue availability, four subjects were included per Braak stage (see Supplementary Table 1) . The results are shown in Fig. 5 . The patterns of protein expression are highly similar to the messenger RNA expression levels for all three proteins. PSEN2 protein expression is significantly regulated during Alzheimer's disease progression (ANOVA, P = 0.02), and we observed a trend for RER1 (P = 0.15) and ZNT3 (P = 0.25). It should be noted that one Braak stage III sample contained ZNT3 levels that were 15Â higher than the other three Braak III samples. When this outlier was removed, changes in ZNT3 levels were highly significant (P = 0.008).
To gain more insight into the levels of intra-and extracellular Ab during the progression of Alzheimer's disease, we performed immunohistochemical staining for Ab in all Braak stages, using the well-characterized antibody 4G8, which recognizes amino acids 17-24 of the Ab peptide. The intracellular and extracellular staining (in the form of diffuse or dense-core plaques) patterns were semi-quantified and blinded to diagnosis (Table 6 ). Photomicrographs of typical staining patterns in each Braak stage are given in Fig. 6 . We observed an increase in intraneuronal staining in Braak stages II and III and a clear decline in intraneuronal staining in more advanced Braak stages. Extracellular 4G8 staining in the form of diffuse plaques occurs mainly in Braak stages 0-I, and in the form of dense-core plaques occurs mainly in Braak stages III and higher.
To investigate the specificity of the observed 4G8 staining patterns we performed a staining with 4G8 serum preabsorbed with Ab42 peptide and 4G8 serum that was treated in exactly the same manner but without addition of the Ab42 peptide. Indeed, 4G8 immunoreactivity was completely abolished in sections incubated with the preabsorbed serum, whereas incubation with control serum resulted in normal 4G8 staining ( Supplementary Fig. 4 ).
Interaction of ApoE genotype with Braak stage profile clusters
To study the potential interaction between ApoE genotype and the clusters of co-regulated genes, we divided the sample set into two groups: (i) individuals with either one (n = 20) or The numbers to the right correspond to the cluster numbers in Supplementary Fig. S3 . (C) The four most significant clusters (defined as the largest fraction of significant genes) during the progression of Alzheimer's disease. The numbers in each plot correspond to the cluster numbers in Supplementary Fig. S3 . The red line indicates the average expression profile of all group members. A list of all Gene Ontology identifiers over-represented in Clusters 6 and 23 with P50.01. Annotated = number of genes on the array with a specific Gene Ontology identifier. In cluster = number of genes in that cluster with a specific Gene Ontology identifier. P-value = TopGO P-value. A list of all Gene Ontology identifiers overrepresented in Clusters 12 and 24 with P50.01. Annotated = number of genes on the array with a specific Gene Ontology identifier. In cluster = number of genes in that cluster with a specific Gene Ontology identifier. P-value = TopGO P-value.
two (n = 1) copies of the ApoE4 allele (the carrier group) and (ii) individuals without an ApoE4 allele (n = 28, the non-carrier group). Subdividing the Braak stages into carriers and non-carriers resulted in groups too small for proper statistical testing. We therefore grouped the samples into three groups: (i) the preclinical 'control' group (Braak stages 0-II); (ii) the 'mild cognitive impairment' group (stages III and IV) and (iii) the 'Alzheimer's disease' group (stages V and VI). For the UPDOWN and DOWNUP clusters, we compared the average expression level of genes contained in that cluster between carriers and non-carriers, for the control, mild cognitive impairment and Alzheimer's disease groups. No differences were observed between carriers and non-carriers in the control or Alzheimer's disease groups. However, for both DOWNUP clusters, we observed a significant increase in expression of the ApoE4 carriers as compared to the non-carriers in the mild cognitive impairment group (Wilcoxon rank sum test50.05, Fig. 7A and B). In the UPDOWN clusters, we observed a trend in the opposite direction, which did not reach statistical significance (Wilcoxon rank sum test 50.15, Fig. 7C and D) . Interestingly, in the mild cognitive impairment group for both the DOWNUP and UPDOWN clusters, the expression level of the carriers resembled those of the Alzheimer's disease group, whereas the distribution of the non-carriers more resembled a transition phase between the control group and the Alzheimer's disease group. Grey genes are not part of the UPDOWN or DOWNUP clusters. Note the upregulation of several potassium voltage-gated channels (KCNS3, KCNB1, KCNA1 and KCNAB1), GABA receptor subunits (GABRA1, GABRD, GABRG2) and genes involved in neurotransmitter exocytosis (SNAP25, CPLX1, VAMP7, SYT1, SYT3, SYT4, NAPB and SV2C). In addition to an increase in exocytosis, a number of genes involved in endocytosis (STON2, CLTC, DNM2, PACSIN1 and TRIP10) are also regulated.
Discussion
By measuring genome-wide gene expression profiles of human prefrontal cortex samples, stratified according to Braak stages for neurofibrillary changes, we were able to demonstrate very early and temporally orchestrated changes in gene expression associated with Alzheimer's disease neuropathology and starting prior to the clinical onset of the disease. A number of gene clusters displayed remarkable concerted alterations in gene expression over the consecutive Braak stages. Genes associated with UPDOWN clusters increase in expression between Braak stages 0 and II, then steeply decline to Braak stage III, followed by a more gradual decline in the advanced Braak stages. This pattern was selectively enriched for genes implicated in synaptic activity and plasticity. The DOWNUP clusters, that for instance include genes involved in differentiation, proliferation and inflammation, follow a roughly mirrored pattern of expression over the Braak stages. Interestingly, the median amyloid plaque score changed dramatically from no plaques at Braak stage II, to many plaques at Braak stage III (Fig. 1) . Also, the first neurofibrillary changes only started to appear after Braak stage II. Thus, in the transition between Braak stages 0 and II, profound gene expression changes are already observed before any of the classical Alzheimer's disease-associated neuropathological changes are present in the prefrontal cortex. It is important to note that the patients in these Braak stages were cognitively unaffected and entered the Netherlands Brain Bank as 'controls' (individuals without any brain pathology, cognitive defects or neurological or psychiatric disorders). The transition between Braak stages II and III thus appears to be very important in Alzheimer's disease progression, not only in terms of neuropathological alterations, but also in terms of changes in gene expression. As the UPDOWN and DOWNUP gene groups already showed strong alterations before the onset of the neuropathological changes in the prefrontal cortex, the individual genes and/or biological processes represented by these gene groups might be causally involved in the development of neuropathology during the progression of Alzheimer's disease.
The appearance of Alzheimer's disease neuropathology in the prefrontal cortex is preceded by changes in gene expression that point to increased synaptic activity and plasticity
The UPDOWN clusters were selectively and significantly enriched for genes involved in synaptic transmission, synaptic plasticity, oxidative phosphorylation and general metabolism (Table 4 and Supplementary Table 5 ). Examples of genes present in UPDOWN clusters that play a role in synaptic plasticity and transmission include cell adhesion molecule with homology to L1CAM (CHL1) and doublecortin-like kinase 1 (DCAMKL1) [both involved in neuron migration and axon outgrowth (Deuel et al., 2006; Koizumi et al., 2006; Schmid and Maness, 2008) Transcriptional evidence for alterations in energy synthesis can be derived from the presence of members of the mitochondrial electron (NADH dehydrogenases: NDUFA10, NDUFA6, NDUFA7, NDUFA9, NDUFB5, NDUFS1, NDUFV2) and proton (ATP synthases: ATP5C1, ATP5F1, ATP5G1, ATP5H, ATP5O, ATP6AP1, ATP6V0E2L) transport complexes. An analysis of the UPDOWN and DOWNUP clusters with ingenuity pathway analysis provided further evidence for very specific changes in synaptic activity in the earliest Braak stages (Fig. 4 and Supplementary Table 6 ). Most interestingly, we observed an increase of genes involved in the exocytosis of neurotransmitters (SNAP25, CPLX1, VAMP7, SYT1, SYT3, SYT4, NAPB and SV2C) and several potassium voltage-gated channels (KCNS3, KCNB1, KCNA1 and KCNAB1), involved in the regulation of the action potential. Synaptotagmin 6 (SYT6), an atypical member of the synaptotagmin family that is relatively excluded from synaptic vesicles (Butz et al., 1999) , is downregulated in Braak stage II. In addition to an increase in exocytosis, a number of genes involved in endocytosis (STON2, CLTC, DNM2, PACSIN1, TRIP10) are also regulated. Three of these genes (STON2, DNM2 and TRIP10) are downregulated, whereas two genes (CLTC and PACSIN1) are upregulated. CLTC and PACSIN1 are involved in activity-dependent bulk endocytosis (Clayton et al., 2009) , whereas DNM2 is involved in the release of nascent vesicles (Bitoun et al., 2009 ) and STON2 in vesicle recycling (Maritzen et al., 2010) . This might indicate a shift in the balance between specific early and late events in endocytosis and vesicle recycling. The increased levels of several gamma-aminobutyric acid receptor subunits (GABRA1, GABRD, GABRG2) suggest a role for inhibitory interneurons in early stages of Alzheimer's disease.
In this context, it is of importance to note that synaptic loss is a prominent feature of Alzheimer's disease (Scheff and Price, 2006) . In contrast, even in end-stage Alzheimer's disease, neuronal loss in the cortex is almost negligible, while neuronal volume is reduced significantly (Regeur et al., 1994) . Our data on decreased expression levels of synaptic transmission-and plasticity-related transcripts might therefore be a reflection of synapse loss and neuronal shrinkage in end-stage Alzheimer's disease. The sharp drop in expression of UPDOWN genes in Braak stage III, however, precedes the massive loss of synapses (Tiraboschi et al., 2000) . To the best of our knowledge, changes in synapse density in the earliest stages of Alzheimer's disease (Braak stages 0-II) have not been reported. Thus, it is highly unlikely that our finding of increased expression of the same set of genes in Braak stages I-II is merely related to changes in tissue composition.
The biological molecular functions of the genes described above, combined with the expression pattern of the UPDOWN clusters over the Braak stages, suggest an increase in the machinery for synaptic activity and plasticity during the progression from Braak stages 0 to II. This is an intriguing finding; individuals in these Braak stages are cognitively unaffected and these early changes in synaptic activity are not paralleled by any classical Alzheimer's disease-associated neuropathological alteration in the prefrontal cortex. Thus, the increased synaptic activity and plasticity might be indicative of deleterious alterations that have a negative effect on synaptic transmission. In this light, the upregulation of genes involved in synaptic activity and plasticity could represent a coping mechanism, where the brain has to 'work' harder to maintain normal cognitive levels. Recent evidence from functional imaging experiments supports our findings of increased neuronal activity in cognitively intact controls, prior to the onset of Alzheimer's disease pathology. Two functional MRI studies comparing aged, but non-demented controls at risk for Alzheimer's disease and non-demented controls not at risk (defined as having or not having a parent who suffered from Alzheimer's disease), demonstrated that the at-risk group showed enhanced activation of the frontal lobe (Bassett et al., 2006; Yassa et al., 2008) . In a familial Alzheimer's disease family characterized by a C410Y mutation in the PSEN1 gene, a cognitively normal 21-year-old carrier exhibited enhanced brain activity as compared with age-matched controls during memory-related tasks (Mondadori et al., 2006) . Interestingly, evidence for a compensatory increase in neuronal activity has Table 6 . The diffuse plaques in Braak stage 0 (white arrow) are age-related and not associated with Alzheimer's disease. Â40 magnification. Green signal represents Hoechst staining for nuclei. also been found in subcortical areas. For example, metabolic activity in the nucleus basalis of Meynert is increased in control cases without an ApoE-"4 allele, and in patients with mild cognitive impairment (Braak stages III-IV) (Dubelaar et al., 2004 (Dubelaar et al., , 2006 .
Increased metabolic activity might therefore represent a compensatory mechanism that exists in neurons throughout the brain.
Increased levels of soluble beta amyloid might underlie the compensatory synaptic activity at early Braak stages
The important question arises of which process(es) elicit the compensatory response of increased synaptic activity at Braak Figure 7 Interaction between UPDOWN and DOWNUP clusters and ApoE genotype. For the four most significant Braak stage clusters, the average fold change per cluster was determined by calculating the mean fold change of all genes in that cluster of the groups 'controls' (Braak stages 0-II), 'mild cognitive impairment' (MCI) (Braak stages III and IV) and 'Alzheimer's disease' (AD) (Braak stages V and VI) . These groups were further subdivided into ApoE4 carriers and non-carriers. P-values were calculated by the Wilcoxon rank sum test. Note the significant ApoE-dependent differences in the mild cognitive impairment group for the DOWNUP clusters (A and B) , and the trend in the UPDOWN clusters (C and D).
stages I-II. Compelling evidence has recently emerged pointing to the inhibitory actions of increased soluble Ab levels on synaptic transmission and plasticity (reviewed in LaFerla et al., 2007) . Direct evidence for a transient impairment of cognitive function by intracerebroventricular infusion of physiological concentrations of Ab oligomers has been demonstrated in non-transgenic rats (Cleary et al., 2005) . In the 3ÂTg-mouse model of Alzheimer's disease, the accumulation of intraneuronal Ab appeared to cause the earliest cognitive defects (Billings et al., 2005) , coinciding with a decline in long-term potentiation (Oddo et al., 2003) , and removal of the intracellular Ab by immunotherapy reversed the cognitive defects (Billings et al., 2005) . Furthermore, both in vitro and in vivo, soluble Ab-mediated synaptic silencing was observed in neurons overexpressing amyloid precursor protein, by specifically targeting postsynaptic -amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors and by reducing presynaptic vesicle recycling (Shemer et al., 2006; Ting et al., 2007) .
By performing immunohistochemical staining in sections of the same samples that were used for the microarray experiment using the well-characterized 4G8 antibody, which is known to recognize intra-and extracellular Ab (both as a free peptide and as part of amyloid precursor protein) (Gouras et al., 2000; Aho et al., 2010; Christensen et al., 2010) , we observed that the increase in expression of genes involved in synaptic plasticity and activity was accompanied by alterations in 4G8 immunoreactivity. Intracellular staining in Braak stages II and III was increased and was followed by a clear decline in intracellular staining in combination with dense-core plaque pathology in more advanced Braak stages (Fig. 6 and Table 6 ). Interestingly, in Braak stage III, both high levels of intracellular 4G8 staining and dense-core plaque pathology were observed. Together with the shifts in gene expression patterns of the UPDOWN and DOWNUP clusters, this may suggest that Braak stage III represents a transition phase where neurons are unable to deal with the high intracellular Ab load, resulting in neuronal dysfunction and Ab aggregation into senile plaques. Also, the increase in transcript levels encoding for synaptic activity and plasticity in Braak stages I-II may possibly represent a compensatory mechanism to deal with the increased intracellular Ab load, as Ab would reduce synaptic efficacy and may elicit a compensatory response to maintain normal levels of synaptic transmission. It should be noted that 4G8 immunoreactivity might be due to other APP cleavage products that contain the Ab peptide, and not the free Ab peptide itself (Aho et al., 2010) .
These observations support the hypothesis that increased intracellular levels of Ab (or APP fragments containing the Ab peptide) precede the formation of dense-core plaques and provide strong evidence for alterations in APP processing and/or Ab load in cognitively unaffected individuals, just before the onset of clinical and neuropathological hallmarks of mild cognitive impairment and Alzheimer's disease. These observations also provide experimental evidence in favour of the hypothesis that there may be a relationship between soluble Ab levels and subsequent plaque formation on the one hand, and the observed changes in gene expression across the Braak stages on the other. It is, however, important to note that the data presented in this paper are insufficient to draw any conclusions on causal or direct interactions between the intra-and extracellular forms of Ab, and/or interactions with the observed changes in gene expression. This interpretation of the data is in our view plausible, but the proposed interactions need to be experimentally validated, and other hypotheses could be formulated based on the present data. For example, an alternative explanation might be that via polysynaptic pathways the first Alzheimer's disease changes in the entorhinal and hippocampal regions affect the function of the neocortex. For this possibility, no evidence is available at present. Indeed, our finding that increased intracellular Ab levels precede plaque formation corroborates earlier findings in both Alzheimer's disease (Gouras et al., 2000; Aho et al., 2010; Christensen et al., 2010) and Down syndrome (Gyure et al., 2001; Mori et al., 2002) , and in several transgenic mouse models for Alzheimer's disease (Oakley et al., 2006; Oddo et al., 2006) .
Transcriptional alterations in the UPDOWN cluster point to increased soluble beta amyloid levels
We systematically studied the list of significantly changed genes in the UPDOWN or DOWNUP clusters, in order to identify genes that might be involved in the observed changes in Ab load and distribution. Indeed, in the UPDOWN clusters, we identified a set of genes (PSEN2, EGR1, RER1, PACAP, SST, PCSK1 and ZNT3) known to be involved in the generation, breakdown or aggregation of Ab (Fig. 8) . The regulatory pattern of these transcripts (upregulated in Braak stages I and II) over the Braak stages provides support for an increased soluble Ab and/or APP load in Braak stages I and II.
Three of these genes (PSEN2, EGR1 and RER1) are involved in gamma-secretase-mediated APP processing. PSEN2 is a member of the gamma-secretase complex and directly catalyzes the cleavage of APP into Ab (Zhang and Xu, 2007) . As PSEN2 contains an EGR1-responsive element in the promoter region, EGR1 regulates the expression of PSEN2 (Renbaum et al., 2003) . RER1 mediates the assembly and intracellular location of the gamma-secretase complex (Kaether et al., 2007; Spasic et al., 2007) .
PACAP regulates Ab levels by promoting the non-amyloidogenic alpha-secretase pathway of APP processing (Kojro et al., 2006) , and is capable of attenuating Ab42-mediated cell death in PC12 cells (Onoue et al., 2002) . SST regulates Ab levels by increasing the activity of neprilysin, the main proteolytic degrading enzyme of Ab (Saito et al., 2005) , and SST levels are increased after administration of Ab25-35 in cultured cortical neurons (Geci et al., 2007) . PCSK1 converts the inactive proprotein pro-somatostatin into SST, and is coexpressed with SST over the Braak stages. Finally, the synaptic zinc transporter ZNT3 releases Zn 2+ into the synaptic cleft upon neuronal activity, which can accelerate plaque formation (Ha et al., 2007) . Indeed, in hAPP+/ZnT3-/-transgenic mice, a significant reduction in plaque load has been observed as compared with hAPP+/ ZnT3+/+ mice (Lee et al., 2002) . Thus, in Braak stages I and II, the increased levels of PACAP, SST and PCSK1 are possibly a response to increased Ab levels, whereas PSEN2, EGR1, RER1 and ZNT3 might induce higher levels of Ab. Western blotting experiments demonstrate changes in the PSEN2, RER1 and ZNT3 protein levels over the Braak stages that are in line with the observed changes in messenger RNA expression. This provides additional support for the hypothesis that alterations in Ab and/or APP load and distribution are associated with changes in expression of these key proteins involved in the generation and deposition of Ab.
The effect of beta amyloid on synaptic transmission and mitochondria possibly underlies the progression from control to mild cognitive impairment/ Alzheimer's disease
In addition to the inhibitory role of Ab on synaptic transmission, recent evidence has emerged that demonstrates that the release of intraneuronal Ab into the extracellular space is directly regulated by neuronal activity. In hippocampal slices of APP SWE mice, neuronal activity modulates the secretion of Ab, and this secretion results in selective and reversible N-methyl-D-aspartic acid receptor-dependent depression of excitatory synaptic transmission (Kamenetz et al., 2003) . Furthermore, Cirrito et al. (2005) very elegantly provided direct in vivo evidence for the relation between synaptic activity and interstitial Ab levels. By simultaneously stimulating the perforant pathway, recording activity in the hippocampus and sampling interstitial fluid, the authors showed that after 1 h of continuous stimulation, interstitial fluid Ab levels increased by 30%. Blocking neuronal activity with tetrodotoxin or tetanus toxin, a decrease of 40% and 70%, respectively, in interstitial fluid Ab levels was observed. All of the changes in Ab levels were reversible, providing compelling evidence that extracellular Ab levels are directly modulated by synaptic activity. Thus, the combined observation that synaptic activity increases extracellular Ab levels and that soluble Ab inhibits synaptic transmission, suggest that under normal physiological conditions, Ab is part of a negative feedback loop preventing neuronal hyperexcitability (Kamenetz et al., 2003) . Taken together, our dataset suggests that an imbalance in this feedback loop might be involved in the rapid appearance of senile plaques in Braak stage III after prolonged periods of increased synaptic activity. In Braak stages I and II, synaptic activity gradually increases as a compensatory response to decreased synaptic efficacy (as a result of increased Ab levels, or other unidentified factors). As Ab secretion is regulated by synaptic activity, more Ab is released into the extracellular space, further decreasing synaptic efficacy. In order to maintain normal cognitive function, synaptic activity must be increased even further. This could lead to a self-amplifying cascade, which ultimately leads to the formation of extracellular plaques.
In addition to the negative effects on synaptic transmission, APP and Ab are also associated with mitochondrial dysfunction. Accumulation of APP and derivatives of APP are found to block mitochondrial import channels in Alzheimer's disease (Devi et al., 2006) . In Tg2576 Alzheimer's disease mice, Ab monomers and oligomers are located on mitochondrial membranes in a transmembrane arrested form (Anandatheerthavarada et al., 2003) . Figure 8 Gene expression changes related to APP processing and Ab metabolism. In the UPDOWN clusters, several genes (EGR1, PSEN2, RER1, PACAP, PCSK1, ZNT3 and SST) are involved in altering the levels of Ab. The expression of these genes is increased in Braak stage II, and decreased in Braak stage IV. This picture reflects the situation at Braak stage II. A detailed discussion of the specific roles of the genes mentioned here on Ab levels can be found in the text. The ? below the -secretase complex indicates the ambivalent effects of increased PSEN2 and RER1 expression on Ab levels.
Thus, the combined effect of Ab on energy synthesis and synaptic transmission/plasticity are a possible explanation for the transition from Braak stages II to III, where decreased activity is accompanied by a sudden increase in senile plaque load.
The ApoE-e4 allele potentially accelerates Alzheimer's disease progression by amplifying gene group changes in the UPDOWN and DOWNUP clusters
In Braak stages III and IV, we observed a striking effect of the ApoE genotype on the magnitude of gene expression changes in the UPDOWN and DOWNUP clusters (Fig. 7) . Regardless of the direction of regulation, carriers of the ApoE-"4 allele exhibited more pronounced alterations in gene expression than non-carriers, suggesting a faster disease progression. Indeed, individuals with one or two ApoE-"4 alleles are known to progress faster from mild cognitive impairment to Alzheimer's disease (Craft et al., 1998; Belbin et al., 2007) . The differential effect of ApoE-"4 versus ApoE-"3 has been studied extensively (reviewed in Mahley et al., 2006) . Amongst others, ApoE-"4 negatively affects neurite outgrowth and remodelling (Nathan et al., 2002; Ji et al., 2003) , enhances Ab deposition (Holtzman et al., 2000) , is associated with altered CNS glucose metabolism (Dubelaar et al., 2004; Reiman et al., 2004; Wishart et al., 2006) and causes mitochondrial dysfunction (Chang et al., 2005; Devi et al., 2006) . There is a striking overlap between processes differentially modulated by the ApoE alleles and the gene groups in the UPDOWN clusters. Thus, the observed changes in gene expression provides strong evidence that during the progression of Alzheimer's disease, ApoE-"4 specifically amplifies processes underlying neurodegeneration, such as reduced synaptic transmission and mitochondrial dysfunction. As our study is too underpowered to detect differences in gene expression between ApoE-"4 carriers and non-carriers on a Braak stage level, it would be of interest to perform additional studies on larger sample groups.
It should be noted that the allele frequency of the ApoE-"4 allele as it is present in the general population is roughly 20%, substantially lower than in our sample selection (42%) (Raber et al., 2004) . This was however our intention, as we aimed to study the potential differences in gene expression due to the ApoE-"4 allele. Therefore, similar numbers of ApoE-"4 carriers and non-carriers needed to be included in each Braak stage.
In addition to ApoE, variations in CLU, PICALM and CR1 have recently been associated with sporadic Alzheimer's disease (Harold et al., 2009; Lambert et al., 2009 ). None of the three genes were differentially expressed in our dataset. Although this might seem surprising, it should be noted that genetic variations in, for example, the ApoE gene are also not reflected in the gene expression level of ApoE itself. It is very possible that the variations in CLU, PICALM and CR1 are reflected in post-translational differences (e.g. different protein folding such as for ApoE). Interestingly, CR1 is the receptor for complement component 4b (C4B) (Birmingham, 1995) , whose expression is significantly altered (a member of the DOWNUP cluster). This suggests that alterations in CR1 signalling or binding might play a role in Alzheimer's disease development. Also, the biological effects of CLU (modulation of Ab aggregation, toxicity and clearance) and PICALM (clathrin-mediated endocytosis) are indeed very similar to the biological processes that we observed to be altered during the progression of Alzheimer's disease (Zlokovic 1996; Harel et al., 2008) .
Neuronal apoptosis and the role of sirtuins in early and late Braak stages
Whereas the gene groups associated with the UPDOWN clusters are in general associated with synaptic activity and plasticity, the neurobiological interpretation of the DOWNUP results in the context of Alzheimer's disease is more difficult. Inflammation and cellular differentiation and/or development appear to be the most important categories. As cellular differentiation or development is usually associated with alterations in transcription factor activities, we examined the genes in the Gene Ontology class 'regulation of transcription, DNA-dependent' more closely for their involvement in Alzheimer's disease-associated neurodegeneration. We observed a concerted upregulation of transforming growth factor beta 1 (TGFB1) and SMAD family member 7 (SMAD7) in end-stage Alzheimer's disease. Interestingly, the expression of these genes is increased in the TgCRND8 mouse model for Alzheimer's disease as a response to Ab, and causes neuronal apoptosis (Salins et al., 2008) . The increased levels of v-rel reticuloendotheliosis viral oncogene homolog A (RELA) and nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1) are also indicative for neuronal apoptosis in the latest Braak stages (Pizzi et al., 2009) . Furthermore, the upregulation of inhibitor of DNA binding 1 and 3 (ID1, ID3) are implicated in Rett Syndrome, a neurodevelopmental disorder. Together, these transcriptional alterations are indicative for neurodegenerative events leading to neuronal dysfunction or neuronal loss in the later Braak stages. Interestingly, the histone deacetylase sirtuin 1 (SIRT1) is co-regulated with these genes. SIRT1 has recently gained attention as a neuroprotective enzyme in Alzheimer's disease and its expression is regulated by resveratrol, a red wine polyphenol associated with a reduced risk for Alzheimer's disease (Anekonda and Reddy, 2006) . Indeed, SIRT1 protects against microglia-dependent Ab toxicity by increasing the acetylation of RELA, thereby inhibiting NF-kappaB signalling (Chen et al., 2005) .
Being a member of the DOWNUP cluster, the expression of SIRT1 is decreased in Braak stages I-II. This downregulation thus occurs at a point in time when the levels of soluble Ab and the metabolic demand (and associated levels of oxidative stress) are increased. One could thus hypothesize that decreased levels of SIRT1-mediated neuroprotection against Ab and apoptosis contribute to causal molecular changes in the progression from control to mild cognitive impairment/Alzheimer's disease. This would also provide a potential mechanistic explanation for the reduced risk for Alzheimer's disease associated with resveratrol intake. This also implies that resveratrol-based treatments should be started before the first clinical signs of the disease. These data warrant further investigation of the role of sirtuins in the earliest Braak stages.
Age-related gene expression changes are notably absent in Alzheimer's disease
In spite of our careful sample inclusion criteria, small differences in age existed between Braak stage groups. To investigate whether age-related gene expression changes may have been present in the set of significantly regulated genes between Braak stages, we compared our list of significantly regulated genes with two published genome-wide gene expression datasets that studied the effect of age on gene expression (Lu et al., 2004; Erraji-Benchekroun et al., 2005) . This comparison yielded only a very small overlap: only 4.2% and 5.7% of the significant genes we report here are also regulated by age (these transcripts are marked in Supplementary Table 4 ). It should be noted that the age range investigated in these studies was far greater than the relatively narrow range included in our study. These data support the conclusion that the significant genes in our study represent distinct Alzheimer's disease-related processes rather than those involved in normal ageing.
Conclusion
In conclusion, we report a number of distinct clusters of genes with concerted alterations over consecutive Braak stages in Alzheimer's disease. The most profound changes occur just before the onset of senile plaque pathology and involve an increase of synaptic activity and plasticity. As these changes are paralleled by increased intracellular Ab and/or APP levels, we propose this to represent a compensatory response to the inhibitory effects of soluble Ab on synaptic transmission. As synaptic activity both regulates the secretion of Ab and is negatively affected by Ab, we hypothesize that disturbances in this balance might cause a positive feedback loop where increasing levels of neuronal activity are paralleled by the observed build-up of Ab. This might ultimately lead to senile plaque formation and a reduction of neuronal activity. These events take place before the first appearance of neurofibrillary changes pathology, and involve alterations in genes and proteins concerned with Ab formation or clearance.
As our data suggest that the interaction between synaptic activity and plasticity and Ab levels are intimately involved in the development of the earliest clinical and neuropathological symptoms of Alzheimer's disease, it is of interest to investigate whether similar mechanisms can also be observed in transgenic animal models for Alzheimer's disease, where APP overexpression is a cardinal feature. Also, familial forms of Alzheimer's disease are characterized by mutations in APP, PSEN1 or PSEN2; this would suggest that similar transcriptional alterations as described here might be present in familial Alzheimer's disease patient samples. Future experiments could shed light on these important questions.
Thus, our data provide support for the amyloid cascade hypothesis, where Ab is the initiating event in Alzheimer's diseaseassociated neuropathology, and in this respect draw a parallel between genetic and sporadic forms of Alzheimer's disease. Furthermore, our findings illustrate the importance of early intervention and suggest that treatment strategies that reduce Ab levels in the earliest stages of Alzheimer's disease might prevent the development of this devastating disease.
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